80 related articles for article (PubMed ID: 22098443)
1. Liver protein profiling in chronic hepatitis C: identification of potential predictive markers for interferon therapy outcome.
Perdomo AB; Ciccosanti F; Iacono OL; Angeletti C; Corazzari M; Daniele N; Testa A; Pisa R; Ippolito G; Antonucci G; Fimia GM; Piacentini M
J Proteome Res; 2012 Feb; 11(2):717-27. PubMed ID: 22098443
[TBL] [Abstract][Full Text] [Related]
2. Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection.
Chen L; Borozan I; Sun J; Guindi M; Fischer S; Feld J; Anand N; Heathcote J; Edwards AM; McGilvray ID
Gastroenterology; 2010 Mar; 138(3):1123-33.e1-3. PubMed ID: 19900446
[TBL] [Abstract][Full Text] [Related]
3. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C.
Asselah T; Bieche I; Narguet S; Sabbagh A; Laurendeau I; Ripault MP; Boyer N; Martinot-Peignoux M; Valla D; Vidaud M; Marcellin P
Gut; 2008 Apr; 57(4):516-24. PubMed ID: 17895355
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
[TBL] [Abstract][Full Text] [Related]
5. Early proteomic analysis may allow noninvasive identification of hepatitis C response to treatment with pegylated interferon α-2b and ribavirin.
Devitt EJ; Power KA; Lawless MW; Browne JA; Gaora PO; Gallagher WM; Crowe J
Eur J Gastroenterol Hepatol; 2011 Feb; 23(2):177-83. PubMed ID: 21164346
[TBL] [Abstract][Full Text] [Related]
6. Liver expression of proteins controlling interferon-mediated signalling as predictive factors in the response to therapy in patients with hepatitis C virus infection.
Bautista D; Bermúdez-Silva FJ; Lasarte JJ; Rodriguez-Fonseca F; Baixeras E
J Pathol; 2007 Nov; 213(3):347-55. PubMed ID: 17940994
[TBL] [Abstract][Full Text] [Related]
7. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.
Yoshizawa K; Abe H; Aida Y; Ishiguro H; Ika M; Shimada N; Tsubota A; Aizawa Y
J Med Virol; 2013 Jul; 85(7):1180-90. PubMed ID: 23918536
[TBL] [Abstract][Full Text] [Related]
8. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy.
Persico M; Capasso M; Persico E; Svelto M; Russo R; Spano D; Crocè L; La Mura V; Moschella F; Masutti F; Torella R; Tiribelli C; Iolascon A
Hepatology; 2007 Oct; 46(4):1009-15. PubMed ID: 17668875
[TBL] [Abstract][Full Text] [Related]
9. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
[TBL] [Abstract][Full Text] [Related]
10. Toll like receptor 3 expression as a novel predictor of response to treatment in chronic hepatitis C virus patients.
Hashad DI; Salem PE; Abdallah DM
Scand J Clin Lab Invest; 2011 Dec; 71(8):641-6. PubMed ID: 22023039
[TBL] [Abstract][Full Text] [Related]
11. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
12. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.
Lange CM; Kutalik Z; Morikawa K; Bibert S; Cerny A; Dollenmaier G; Dufour JF; Gerlach TJ; Heim MH; Malinverni R; Müllhaupt B; Negro F; Moradpour D; Bochud PY;
Hepatology; 2012 Apr; 55(4):1038-47. PubMed ID: 22095909
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
14. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
15. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.
Walsh MJ; Jonsson JR; Richardson MM; Lipka GM; Purdie DM; Clouston AD; Powell EE
Gut; 2006 Apr; 55(4):529-35. PubMed ID: 16299039
[TBL] [Abstract][Full Text] [Related]
16. Pegylated interferon treatment in HCV genotype 2 and 3 patients refractory to conventional interferon.
Aziz S
J Coll Physicians Surg Pak; 2012 Oct; 22(10):615-6. PubMed ID: 23058141
[No Abstract] [Full Text] [Related]
17. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I
J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection.
Brost S; Zimmermann A; Koschny R; Sykora J; Stremmel W; Schirmacher P; Walczak H; Ganten TM
Pathol Res Pract; 2014 Feb; 210(2):83-91. PubMed ID: 24268735
[TBL] [Abstract][Full Text] [Related]
19. [Chronic hepatitis C virus infection: clinical picture and treatment possibilities].
Annicchiarico BE; Siciliano M; Gasbarrini A
G Ital Nefrol; 2012; 29 Suppl 54():S103-8. PubMed ID: 22388839
[TBL] [Abstract][Full Text] [Related]
20. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
